Credit Suisse Starts AC Immune SA (ACIU) at Outperform
- Top 10 News for 10/24 - 10/28: AT&T (T), Time Warner Make it Official; Margins Hamper Apple's Q4; Mergers Aplenty
- Wall St. falls as FBI to review more Clinton emails
- Clinton email problem resurfaces as FBI announces review
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Credit Suisse initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $18.00.
Analyst Alethia Young commented, "AC Immune is focused on neurodegenerative diseases, primarily Alzheimer’s Disease (AD). Their lead asset, crenezumab, is in Phase 3 in partnership with Roche. AC Immune is developing more than just crenezumab which allows for some optionality with early AD targets like Tau or AD vaccines. In this report, we will focus on near-term catalyst which will be a stock read-through from a competitive Phase 3 program being developed by Lilly. We view this story as high risk/high reward in the nearterm. In the long-term post the headline risk, we are positive for 3 reasons: 1) no AD asset is exactly the same and designs differ so it will be uncertain that if solanezumab (Sola) fails all drugs fail, 2) their Ph3 and Biogen's (another competitor) will continue even if Lilly is a complete fail, and 3) AC Immune has other assets that could be used in combination or separately from crenezumab."
Shares of AC Immune SA closed at $14.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Partners Downgrades McKesson (MCK) to Market Perform
- Jefferies Raises Price Target on Bristol-Myers Squibb (BMY) Following 3Q
- Alphabet (GOOGL) (GOOG) PT Raised to $925 at Needham & Company
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Related EntitiesCredit Suisse
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!